Empirical study of Pseudomonas aeruginosa exotoxin A targeting on hepatocellular carcinoma in vitro

Abstract

Abstract: AIM: To construct a gene-modified hepatocellular carcinoma (HCC) specific PE38 expression vector regulated by cis-acting element of AFP, and explore its anti-HCC effect in vitro. METHODS: Eukaryotic expression plasmid pAFP-PE38 was constructed and then transfected into different cell lines.The expression level of PE38 mRNA was detected by RT-PCR. Cytotoxicity was detected by cell counting kit-8 (CCK-8). RESULTS: PE38 mRNA was detected only in AFP-positive HepG2 cells after plasmid transfection. Significant morphological changes and growth inhibition (P＜0.01) were observed in HepG2 cells, the inhibition rate at 48 h and 72 h were 27.2% and 58.3%,respectively; whereas no such changes were found in AFP-negative PC-3 cells and HeLa cells. CONCLUSION: PE38 gene eukaryotic expression vector can selectively targets on HCC cells with high efficacy, which might be used as an effective tool for HCC gene therapy.

Key words: PE38, α-fetoprotein, Gene therapy

CLC Number:

R965.2

LIU Yang, WU Jin-ming, JIN Si-si, SHEN Su-jian, WU Li-min, JIANG Hong-feng, JIN Yin. Empirical study of Pseudomonas aeruginosa exotoxin A targeting on hepatocellular carcinoma in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 372-375.

References

[1] Guan M, Rodriguez-Madoz JR, Alzuguren P, et al. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector[J]. Cancer Res, 2006, 66(3): 1620-1629.
[2] 许瑞安,刁勇,谢海棠. 基因药物在临床上的最新应用与研发[J].中国临床药理学与治疗学, 2006, 11(10):1092-1097.
[3] Liu RS, Hsieh YJ, Ke CC, et al. Specific activation of sodium iodide symporter gene in hepatoma using alpha-fetoprotein promoter combined with hepatitis B virus enhancer (EIIAPA)[J]. Anticancer Res, 2009, 29(1): 211-221.
[4] Hirano T, Kaneko S, Kaneda Y, et al. HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice[J]. Gene Ther,2001, 8(1): 80-83.
[5] Yoshihiko M, Koichiro K,Masaki K.Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene[J]. Surg Oncol, 1999, 70(3): 145-149.
[6] Ido A, Uto H, Moriuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human a-fetoprotein promoter[J]. Cancer Res, 2001, 61(7): 3016-3021.
[7] Wolf P, Elsasser-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent[J]. Int J Med Microbiol, 2009, 299(3): 161-176.
[8] Pastan I, Chaudhary V, FitzGerald DJ. Recombinant toxins as novel therapeutic agents[J]. Annu Rev Biochem, 1992, 61: 331-354.
[9] 曹广文,戚中田,粟山茂树,等. 假单胞菌外毒素基因的克隆及用于裸鼠大肠癌基因治疗[J]. 第二军医大学学报,1998, 19(2): 106-109.
[10] 曹广文,潘欣,张晓琴,等. 人CEA启动子调控ADP核糖化毒素基因治疗大肠癌[J]. 肿瘤,2000, 20(3): 167-170.

[1]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[2]	JIANG Bingbing. Research progress on microRNAs in Huntington's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 677-685.
[3]	LI Zheng, XIANG Kai-ming, PENG Shu-ping, LI Gui-yuan. Basic research of microRNA-34 for cancer therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 67-73.
[4]	LV Ying-hui, GONG Yu-hua, DIAO Yong, XU Rui-an, WANG Qi-zhao. HMGA2 play important roles both in tumorigenesis and angiogenesis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 975-980.
[5]	LIU Mo-jun, LIU Yan-ping, LIU Xiong-hao. Gene therapy for hemophilia A [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 932-937.
[6]	TAO Hong, CHEN Li-xin, CEN Ming, LIN Jiang. Effects of adenoviral vector mediated Fas ligand gene introduction on the medial layers of vascular smooth muscle cell density after rat carotid artery injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1401-1403.
[7]	WANG Qi-zhao, LV Ying-hui, XU Rui-an. Dose-response and control of adeno-associated viral vectors based preclinical and clinical gene therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1182-1194.
[8]	ZHANG Liu-fu, HUANG Qiong, CHU Lan. Progress in treatment of multiple sclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 499-503.
[9]	DING Ya, ZHANG Xiao-shi, PENG Rui-qing, ZHANG Rong, ZHANG Nian-hua, LI Zhi-ming, LIU Ji-yan, MA Jin, CHENG Xia, SU Yi-shun, ZENG Yi-xin. Safety and primary efficacy of recombinant human adenovirus-p53 injection on advanced solid tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1025-1029.
[10]	Wuyuan-xiong, WANG Jin-ming, ZHANG Mei-chun, LIANG Yuan-hong. Protection effect of β₁ receptor mRNA antisense inhibition on heart of renal hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(10): 1123-1127.
[11]	SHAN Shou-Jie, CHEN Shao-Liang. Transplantation of marrow stem cell on ischemic heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 473-476.